Keyphrases
Diabetes Status
100%
Major Coronary Events
100%
Lipoprotein-associated Phospholipase A2 (Lp-PLA2)
100%
Scotland
38%
Phospholipase A2 Inhibitor
38%
Tayside
33%
Diabetes Genetics
33%
Darapladib
33%
Diabetes
28%
Atherosclerotic Plaque
28%
Placebo
14%
High-risk Population
14%
Diabetes Control
14%
Control Status
14%
Low Activity
9%
Type 2 Diabetes Mellitus (T2DM)
9%
Hemoglobin A1c (HbA1c)
9%
Poorly Controlled Diabetes
9%
Access Management
4%
Medical Records
4%
Population Specificity
4%
High Risk
4%
Type 2 Diabetic Patients
4%
Cardiovascular Mortality
4%
Cardiovascular Morbidity
4%
Glycemic Control
4%
Retrospective Cohort Study
4%
GlaxoSmithKline
4%
Trial Data
4%
Cox Proportional Hazards Model
4%
Cohort-based
4%
Management Group
4%
Stratified Analysis
4%
Cohort Design
4%
Type 2 Diabetes Diagnosis
4%
Trial Records
4%
Pharmacology, Toxicology and Pharmaceutical Science
1 Alkyl 2 Acetylglycerophosphocholine Esterase
100%
Darapladib
33%
Phospholipase A2 Inhibitor
23%
Non Insulin Dependent Diabetes Mellitus
19%
Placebo
14%
Clinical Study
4%
Cohort Study
4%
Population Study
4%
Biochemistry, Genetics and Molecular Biology
Lipoprotein-Associated Phospholipase A2
100%
Genetics
33%
High Risk Population
19%
Cohort Study
4%
Medical Record
4%
Clinical Study
4%
Glycemic Control
4%
Population Research
4%